RecruitingPhase 2NCT07014319

Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies

Maribavir Treatment of Cytomegalovirus for Lymphoid Malignancy Patients Undergoing Bispecific Antibodies

Sponsor

Seoul National University Hospital

Enrollment

20 participants

Start Date

Nov 3, 2025

Study Type

INTERVENTIONAL

Conditions

Cytomegalovirus (CMV)

Summary

This is an open-label, single arm, multicenter study to evaluate the feasibility of maribavir treatment in multiple myeloma and lymphoma patients undergoing bispecific antibody treatment and experiencing treatment emergent CMV events

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study is testing the antiviral drug maribavir in blood cancer patients (multiple myeloma or lymphoma) who are receiving bispecific antibody treatments and develop a viral infection called cytomegalovirus (CMV) — a common and potentially serious complication in this group. **You may be eligible if...** - You are 19 years old or older - You have multiple myeloma or a type of B-cell lymphoma currently being treated with a bispecific antibody (such as teclistamab, mosunetuzumab, epcoritamab, or similar drugs) - You have developed a significant CMV infection (either organ disease or elevated virus levels in your blood) - You are in good enough health to participate (ECOG score 0, 1, or 2) **You may NOT be eligible if...** - You do not have a documented CMV infection as defined by the study - You are not currently on one of the specified bispecific antibody treatments - You are pregnant or unable to use adequate contraception Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMaribavir

Participants will receive maribavir 400 mg twice daily starting from Week 1 and continuing until clearance of CMV. CMV clearance is defined as either an unquantifiable plasma CMV DNA titer (i.e., below the lower limit of quantification \[LLOQ\]) as assessed by the local laboratory, or a CMV DNA level below 500 IU/mL in plasma without evidence of CMV disease.